Savara Inc (NASDAQ:SVRA) shares saw unusually-strong trading volume on Tuesday . Approximately 1,915,775 shares were traded during trading, an increase of 1,030% from the previous session’s volume of 169,472 shares.The stock last traded at $10.70 and had previously closed at $9.65.
Several analysts recently commented on SVRA shares. Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, March 2nd. BidaskClub upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. ValuEngine upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Monday, April 1st. LADENBURG THALM/SH SH restated a “buy” rating and set a $21.00 price target on shares of Savara in a report on Monday, April 1st. Finally, Canaccord Genuity set a $22.00 price target on shares of Savara and gave the stock a “buy” rating in a report on Monday, March 25th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $21.17.
The company has a debt-to-equity ratio of 0.23, a quick ratio of 15.63 and a current ratio of 15.63. The firm has a market capitalization of $383.38 million, a P/E ratio of -8.29 and a beta of 0.86.
In other Savara news, COO Jaakko Taneli Jouhikainen sold 7,815 shares of Savara stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $9.00, for a total value of $70,335.00. Following the completion of the sale, the chief operating officer now directly owns 184,754 shares in the company, valued at $1,662,786. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David L. Lowrance sold 7,500 shares of Savara stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $9.02, for a total transaction of $67,650.00. Following the completion of the sale, the chief financial officer now owns 2,446 shares of the company’s stock, valued at $22,062.92. The disclosure for this sale can be found here. Insiders sold 42,761 shares of company stock valued at $385,749 over the last quarter. Corporate insiders own 6.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of SVRA. Simplex Trading LLC lifted its stake in Savara by 246.1% in the fourth quarter. Simplex Trading LLC now owns 4,997 shares of the company’s stock valued at $37,000 after acquiring an additional 3,553 shares during the last quarter. Virtu Financial LLC acquired a new stake in Savara in the fourth quarter valued at approximately $82,000. Jane Street Group LLC acquired a new stake in Savara in the fourth quarter valued at approximately $93,000. D. E. Shaw & Co. Inc. acquired a new stake in Savara in the fourth quarter valued at approximately $111,000. Finally, Alliancebernstein L.P. acquired a new stake in Savara in the third quarter valued at approximately $118,000. Hedge funds and other institutional investors own 48.42% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2019/04/24/savara-svra-sees-strong-trading-volume.html.
About Savara (NASDAQ:SVRA)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.